Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Why I’m accumulating

<< Previous

Bullboard Posts

Next >>

Comment by clubhouse19on Feb 19, 2021 10:04am

143 Views

Post# 32608521

RE:RE:RE:Why I’m accumulating

It's a bought deal so the closing date is really a moot point.

The onus is on the underwriters to sell all their allocated shares preferably by the 24th when they have to hand over the money filled or not !

3burtc wrote: This financing closes next week which is SUPER FAST! U.S. pharma partner agreement just around the corner? This will be the Big One! Nuance is great but small compared to what we're heading towards. Glta, up, up,up we go!

<< Previous

Bullboard Posts

Next >>

Enbridge finalizes acquisition of three growing gas utilities